Gracell Biotechnologies  logo
Gracell Biotechnologies GRCL

Quarterly report 2022-Q2
added 08-15-2022

report update icon

Gracell Biotechnologies Cash Flow 2011-2026 | GRCL

Annual Cash Flow Gracell Biotechnologies

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-305 M -198 M -135 M -61.9 M - - - - - - -

Depreciation & Amortization

44.9 M 21.6 M 5.12 M 2.99 M - - - - - - -

All numbers in CNY currency

Quarterly Cash Flow Gracell Biotechnologies

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

All numbers in CNY currency

Cash Flow Statement is one of the three key financial reports of the company Gracell Biotechnologies , reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
BioNTech SE BioNTech SE
BNTX
$ 97.54 2.14 % $ 27.2 B germanyGermany
Aligos Therapeutics Aligos Therapeutics
ALGS
$ 8.65 8.19 % $ 85.5 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.63 -2.42 % $ 8.73 B australiaAustralia
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Esperion Therapeutics Esperion Therapeutics
ESPR
$ 2.14 -1.38 % $ 445 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
$ 0.81 -0.07 % $ 27.9 M israelIsrael
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 20.47 0.49 % $ 957 M usaUSA
Genmab A/S Genmab A/S
GMAB
$ 28.2 -0.18 % $ 18 B danmarkDanmark
Grifols, S.A. Grifols, S.A.
GRFS
$ 8.19 -0.24 % $ 6.83 B spainSpain
GT Biopharma GT Biopharma
GTBP
$ 0.36 -2.82 % $ 1.98 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Halozyme Therapeutics Halozyme Therapeutics
HALO
$ 67.06 -1.12 % $ 8.04 B usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
$ 28.69 -0.69 % $ 1.65 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 1.41 0.71 % $ 363 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 2.96 1.37 % $ 4.87 M israelIsrael
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.16 1.84 % $ 445 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 24.01 -0.85 % $ 3.05 B usaUSA
ImmuCell Corporation ImmuCell Corporation
ICCC
$ 7.12 1.14 % $ 64.3 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 32.24 - $ 2.14 B usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.48 -0.67 % $ 394 M britainBritain
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Immatics N.V. Immatics N.V.
IMTX
$ 10.48 0.43 % $ 659 M germanyGermany
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
Incyte Corporation Incyte Corporation
INCY
$ 94.86 -1.26 % $ 18.5 B usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
$ 2.61 2.35 % $ 16.4 M usaUSA
InflaRx N.V. InflaRx N.V.
IFRX
$ 1.05 4.5 % $ 152 M germanyGermany
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Inventiva S.A. Inventiva S.A.
IVA
$ 5.18 -1.52 % $ 138 M franceFrance